What is Aptamer Group PLC's (APTA.L) StockRank?

MoatMap's StockRank for Aptamer Group PLC (APTA.L) is 3/100, with a Strong Sell signal. This is a composite score combining Quality (24), Value (34), and Momentum (17) factor ranks across MoatMap's 20,000+ stock universe.

Does Aptamer Group PLC have an economic moat?

Aptamer Group PLC (APTA.L) has a Quality factor score of 24/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Aptamer Group PLC a buy, hold, or sell?

MoatMap's current signal for Aptamer Group PLC (APTA.L) is Strong Sell, based on a StockRank of 3/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Aptamer Group PLC in?

Aptamer Group PLC (APTA.L) operates in the Healthcare sector, specifically the Biotechnology industry (United Kingdom).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

APTA.L

STRONG SELLREMOVE

Aptamer Group PLC · Healthcare · United Kingdom · $28M · Avg Vol: $18K/d

StockRank

P/E (TTM)

—

ROE

-102.2%

D/E

0.1x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Aptamer Group is a microcap healthcare firm with high cash burn and unproven commercial scale, failing our fundamental quality and margin of safety filters.

COMPANY DESCRIPTION

Aptamer Group PLC develops custom affinity binders called Optimers, which serve as synthetic alternatives to antibodies for use in diagnostics, therapeutics, and life sciences research. The company's proprietary Optimer platform offers significant advantages over traditional antibodies, including rapid development times, high specificity, and cost-effective manufacturing. It operates as a high-growth, IP-rich biotechnology partner, licensing its technology to global pharmaceutical and diagnostic developers.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	5M	2M	1M	2M	-33.2%
EPS	-0.04	-0.15	-0.01	-0.00	—
Shares	69M	69M	467M	2.0B	+2785.1%
Debt	2M	1M	1M	659,175	-27.9%
Equity	11M	408,125	1M	2M	-44.4%
Op CF	-3M	-5M	-3M	-3M	—
Inv CF	-561,172	-3M	-163,787	-123,511	—
Fin CF	12M	-490,018	4M	3M	—

PRICE (1M)-20.8%

SMA 50SMA 200

$0.01

RSI (14)

20.0

52W High

$0.02

From 52W High

0.3%

SCORE BREAKDOWN

Quality

ROIC

-151.5%3.1

ROE

-102.2%7.9

GP/Assets

23.5%53.7

Op. Margin

-149.5%15.2

FCF/Assets

-43.5%5.4

Piotroski

—7.2

Int. Cover

-44.9x13.4

D/E Ratio

0.15x58.9

Current Ratio

2.04x37.9

Value

P/E (TTM)

—N/A

EV/EBITDA

-5.2x74.0

P/FCF

—N/A

P/B

5.5x21.6

P/S

13.7x21.6

Div Yield

—N/A

Momentum

52W High %

30%6.0

RS 6M

-45%26.2

SMA 50/200

0.71x6.1

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$28M

P/E (Forward)

—

Gross Margin

48.8%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of APTA.L are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
APTA.L	Aptamer Group PLC(you)	$28M	3	STRONG SELL
IMM.L	ImmuPharma plc	$37M	1	STRONG SELL
SAR.L	Sareum Holdings plc	$47M	14	STRONG SELL
SBTX.L	SkinBioTherapeutics plc	$34M	21	SELL
HEMO.L	Hemogenyx Pharmaceuticals Plc	$63M	14	STRONG SELL
IXI.L	IXICO plc	$25M	29	SELL
4BB.L	4basebio PLC	$110M	5	STRONG SELL
TLSA	Tiziana Life Sciences Ltd	$186M	1	STRONG SELL
POLB.L	Poolbeg Pharma PLC	$56M	39	HOLD
BCYC	Bicycle Therapeutics plc	$326M	11	STRONG SELL

Peer medians: ROE 1.2% · P/E 26.9x · Gross margin 51.4%

Aptamer Group PLC (APTA.L) — Stock Score Summary

Aptamer Group PLC (APTA.L) has a MoatMap StockRank of 3/100 based on Quality (24/100), Value (34/100), and Momentum (17/100) factor scores. The current signal is STRONG SELL. Aptamer Group is a microcap healthcare firm with high cash burn and unproven commercial scale, failing our fundamental quality and margin of safety filters.

Key Financial Metrics

Price	$0.01
Market Cap	$28M
Price/Book	5.47
Return on Equity	-102.2%
Return on Invested Capital	-151.5%
Debt/Equity	14.78
Gross Margin	48.8%
Operating Margin	-149.5%
Revenue Growth	26.8%
Free Cash Flow	$-2M

Aptamer Group PLC operates in the Biotechnology industry, part of the Healthcare sector (United Kingdom).

Frequently Asked Questions

What is Aptamer Group PLC’s (APTA.L) StockRank?: MoatMap’s StockRank for Aptamer Group PLC (APTA.L) is 3/100, with a Strong Sell signal. It is a composite of Quality (24), Value (34), and Momentum (17) factor ranks across MoatMap’s 20,000+ stock universe.
Does Aptamer Group PLC have an economic moat?: Aptamer Group PLC (APTA.L) has a Quality factor score of 24/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Aptamer Group PLC a buy, hold, or sell?: MoatMap’s current signal for Aptamer Group PLC (APTA.L) is Strong Sell, based on a StockRank of 3/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Aptamer Group PLC in?: Aptamer Group PLC (APTA.L) operates in the Healthcare sector, specifically the Biotechnology industry (United Kingdom).